DENVER, Colo. (247marketnews.com) -- Scancell Holdings (AIM:SCLP) and Neuphoria Therapeutics (NASDAQ:NEUP) have unveiled a transformative all-share merger designed to position the combined company for its next stage of clinical and commercial growth. Upon closing, the combined business will operate under the Scancell name and intends to list on NASDAQ under the proposed ticker SCLT, while maintaining Scancell's existing AIM listing. The transaction combines Scancell's late-stage immunotherapy pipeline with Neuphoria's public market platform and remaining cash resources, creating a company focused on advancing active cancer immunotherapies with expanded access to U.S. capital markets.
The merger is accompanied by a financing package of up to $89 million, including a $39.1 million private placement, approximately $15 million from UK institutional and retail offerings, up to $25 million in debt financing supported by funds managed by BlackRock, and at least $10 million of expected cash from Neuphoria at closing. Management expects the financing to fund the registrational Phase 3 trial of iSCIB1+ in advanced melanoma while extending the company's projected cash runway into 2029. The transaction remains subject to shareholder approvals, regulatory review, Nasdaq listing approval, and other customary closing conditions.
Scancell's lead immunotherapy candidate, iSCIB1+, represents the central value driver behind the transaction. The company noted that the FDA has granted the program Fast Track designation, while Phase 2 data demonstrated 77% progression-free survival at 22 months when administered alongside ipilimumab and nivolumab in advanced melanoma patients. Additional Phase 2 progression-free survival and overall survival data are expected within the next year, potentially setting the stage for the planned global registrational Phase 3 study.
For Neuphoria, the merger provides shareholders continued exposure to potential future value through Contingent Value Rights (CVRs) tied to partnered assets, intellectual property monetization, and an Australian R&D tax credit, while allowing the combined company to concentrate resources on Scancell's oncology pipeline. Neuphoria previously halted development of its lead anxiety therapy following disappointing Phase 3 results and has been conducting a strategic review, making the merger a significant strategic pivot for the company.
The announcement underscores a broader trend across biotechnology, where companies increasingly leverage mergers, cross-border listings, and strategic financings to secure sufficient capital for late-stage clinical development. With a planned NASDAQ listing, strengthened balance sheet, and a Phase 3-ready oncology program, Scancell aims to broaden its institutional investor base while accelerating development of its differentiated cancer immunotherapy platform.
Sources
Scancell Holdings – Merger Announcement: https://www.scancell.co.uk/
Neuphoria Therapeutics (NASDAQ: NEUP): https://www.neuphoria.com/
U.S. Securities and Exchange Commission Filings: https://www.sec.gov/
London Stock Exchange AIM: https://www.londonstockexchange.com/markets/aim
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.